Evonik Industries : makes five generations healthier with EUDRAGIT® coatings for targeted drug delivery

Press release

Health Care

Essen, Germany, March 14, 2024

Evonik makes five generations healthier with EUDRAGIT® coatings for targeted drug delivery

• Over 23,000 patents with EUDRAGIT® in 70 years
• More than 10,000 scientific publications containing EUDRAGIT®
• Rooted in history, innovation with EUDRAGIT® is increasing Evonik's share of system solutions

EUDRAGIT® polymers have been used as coatings to create more effective drugs for 70 years. Over the decades, the portfolio of methacrylate polymers has established itself as the industry standard with more than 23,000 patents and 10,000 scientific publications¹ mentioning the EUDRAGIT® brand. Today, customers in over 80 countries use EUDRAGIT® polymers in their formulations for modified release.

With its long-standing experience in functional excipients, formulation and application services, Evonik provides EUDRAGIT® polymers as key ingredients in multi-component systems that are tailored to a unique and specific customer need. These system solutions are driving a transformation within Evonik's life sciences division, Nutrition & Care, which is leveraging its expertise in biosolutions to increase its share of system solutions to 70 percent by 2032.

"From baby boomers to generation alpha, we are proud to have been enabling pharmaceutical innovation with EUDRAGIT® from day one, improving health outcomes around the world," said Thomas Riermeier, head of the Health Care business line at Evonik.

EUDRAGIT® is the industry's preferred portfolio of functional polymers for use with oral drug products. The breadth, versatility and history of EUDRAGIT®, combined with Evonik's range of drug delivery technologies, formulation and cGMP manufacturing services, provides pharmaceutical companies with unrivalled safety, supply security and functional reliability for their oral solid dosage forms.

"Nearly everyone you know will have come into contact with EUDRAGIT® at some point in their lives," said Paul Spencer, head of Drug Delivery & Products at Evonik. "With a growing and aging population, we look forward to continuing to innovate these polymers into next-generation solutions, such as the recently launched EUDRACAP® which is fast becoming a leading choice for enteric capsule protection."

EUDRAGIT® polymers are polymethacrylates suitable for use in drug delivery applications. Since 1954, Evonik has developed more than 20 types of EUDRAGIT® polymers that are ideal for all solid oral dosage forms including multi-particulates, regular or matrix tablets and hard or soft-gel capsules. EUDRAGIT® polymers can be used individually or in combination to match virtually any target release profile including immediate, delayed and sustained release. They are also compatible with all relevant process technologies including hot melt extrusion and spray drying for solubility enhancement.

Evonik's Health Care business line, which is part of the Nutrition and Care division of Evonik, is one of the world's leading integrated CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world's largest pharmaceutical suppliers of generic APIs, amino acids and cell culture ingredients, and a top CDMO for APIs and intermediates.

_{¹ Information about patents is taken from PatentSight. Number of publications according to EBSCO Discovery Service Indexes which contains scientific publications from a wide range of publishers.}